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milk and infant formulas) actually enters 
the circulation; the omega-3 fatty acids, 
as essential nutrients, must be largely or 
entirely obtained from the diet (Cansev and 
Wurtman, 2007). Because the enzymes that 
initiate the conversion of these compounds 
to PC are unsaturated, the administration 
of choline increases the synthesis and brain 
levels of its phosphorylated product phos-
phocholine; that of uridine increases UTP 
and CTP; and that of DHA increases the 
proportion of diacylglycerol (DAG) that 
contains this omega-3 fatty acid.
The phosphocholine and CTP formed 
when animals receive uridine plus choline 
then combine to form CDP-choline, which 
in turn combines with DHA-containing 
DAG to form PC. Treatment of rats or ger-
bils with supplemental choline, UMP, and 
an omega-3 fatty acid for several weeks is 
associated with substantial increases in lev-
els of PC per brain or per brain cell, as well 
as roughly-proportionate increases in the 
other phosphatides (Wurtman et al., 2006); 
moreover the effects of giving all three pre-
cursors tend to be greater than the sum of 
the effects of giving each separately. Animals 
so treated also exhibit significant improve-
ments in memory functions, as assessed 
using the Morris water maze and T- or 
Y-mazes (Holguin et al., 2008a,b).
Administration of the three phosphatide 
precursors also increases brain levels of 
pre- and post-synaptic proteins (such as 
synapsin, synaptophysin, PSD-95, and 
mGluR) (Wurtman et al., 2006; Cansev 
and Wurtman, 2007) as well as the num-
bers of dendritic spines (Sakamoto et al., 
2007). These effects are due in part to an 
additional effect of the pyrimidine uridine 
(Pooler et al., 2005): Besides serving, indi-
rectly, as a CTP precursor in cytidine-de-
pendent phosphatide synthesis, uridine and 
its phosphorylated products (e.g., UTP) are 
also agonists for P2Y receptors that affect 
neuronal protein synthesis (Pooler et al., 
2005). (These receptors, parenthetically, 
are deficient in parietal cortex of patients 
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The loss of hippocampal and cortical 
synapses, resulting from impaired syn-
aptogenesis, accelerated synaptic degen-
eration, or both, is one of the earliest 
neuropathologic findings in Alzheimer’s 
Disease and is the finding that best cor-
relates with cognitive symptoms (DeKosky 
and Scheff, 1990; Terry et al., 1991; Selkoe, 
2002). A similar decrease in brain synapses 
is an early finding in an animal model of 
AD which overproduces A-beta peptides 
(Jacobsen et al., 2006), and aggregates of 
such peptides, applied locally to the brain, 
can also damage synapses, distort neurites, 
and decrease the numbers of the dendritic 
spines which are essential precursors for 
glutamatergic synapses (Jacobsen et al., 
2006; Spires-Jones et al., 2007; Knobloch 
and Mansuy, 2008). These observations 
have supported the widely-held view that 
a treatment that would block the synthesis 
of A-beta or remove it from the circula-
tion, might – by depleting its levels in 
brain – slow the loss of synapses in AD 
and thereby sustain cognitive functions 
in patients. A generation of creative and 
diligent researchers has provided us with 
abundant information about A-beta’s 
synthesis, fates, and toxic effects, and this 
information has been used to generate 
rationally-designed drug candidates for 
treating the disease. However to date none 
of these candidates – even ones shown to 
reduce brain levels of A-beta oligomers 
and senile plaques – has been successful 
in sustaining cognition.
In the future perhaps another drug can-
didate might succeed both in reducing brain 
levels of A-beta peptides and ameliorating 
the dementia of Alzheimer’s Disease; man-
kind appears united in the hope that this 
will be the case. However in the interim 
might there be additional therapeutic strat-
egies which we can pursue in parallel which, 
if successful, might provide patients with 
more benefit than they presently obtain 
from the acetylcholinesterase inhibitors or 
glutamate antagonist now in use?
One such strategy might entail finding a 
treatment that, by accelerating synaptogen-
esis, would diminish the net loss of hippoc-
ampal and cortical synapses caused by AD. 
There are a number of loci at which such 
a treatment might work: For example, it 
might amplify the flux of free calcium into 
stimulated dendrites, or activate receptors 
that control key steps in forming dendritic 
spines, or increase the synthesis of pre- or 
post-synaptic proteins, or generate more 
synaptic membrane, the main constituent 
of synapses. One such treatment, described 
below, has been proposed based on studies 
in experimental animals, and is currently 
being tested in patients. Its intent is to 
promote synaptogenesis by administering 
phosphatide precursors which, in test ani-
mals, increase the production of synaptic 
membrane and dendritic spines (Wurtman 
et al., 2006; Sakamoto et al., 2007). The 
three precursors required to form the phos-
phatides – uridine; an omega-3 fatty acid 
such as docosahexaenoic acid (DHA); and 
choline – all readily cross the blood-brain 
barrier (Wurtman et al., 2009).
Synaptic membrane is composed prin-
cipally of phospholipids – particularly 
the phosphatides phosphatidylcholine 
(PC), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), and phosphati-
dylinositol (PI) – as well as characteristic 
pre- and post-synaptic proteins. Formation 
of the phosphatides from their three circu-
lating precursors is mediated by enzymes 
that exhibit relatively low affinities for 
these substrates, and thus are unsaturated 
at the precursor concentrations normally 
present in the blood and brain. The circulat-
ing choline is obtained from various foods 
and is also synthesized in and secreted from 
the liver (Wurtman, 2009; Wurtman et al., 
2009); the uridine, also produced in and 
released from the liver, is present in many 
foods in the form of RNA, however there 
is no satisfactory evidence that uridine in 
dietary RNA (unlike that present as urid-
ine monophosphate [UMP] in mothers’ 
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with AD [Lai et al., 2008]). DHA alone can 
also stimulate neurite outgrowth (Darios 
and Davletov, 2006) and dendritic spine 
formation (Sakamoto et al., 2007), possibly 
by activating other receptors.
Existing technologies have not allowed 
the direct measurement of hippocampal syn-
apse formation in animals receiving the three 
phosphatide precursors. However the con-
sensus among synaptologists seems to be that 
an increase in dendritic spines as produced 
by the precursors virtually always leads to an 
increase in synapses: It has been estimated 
that 90% or more of the spines become 
synapses (c.f. Alvarez and Sabatini, 2007; 
Arellano et al., 2007; Toni et al., 2007).
In an initial clinical trial, 110 patients 
with very mild or mild AD received the pre-
cursors for 6 weeks while an equal number 
served as controls; those in the treated 
group exhibited a statistically-significant 
improvement in memory compared with 
control subjects (Scheltens et al., 2010). 
It remains to be determined whether this 
improvement was, in fact, associated with an 
increase in the numbers of cortical and hip-
pocampal synapses. Three additional large-
scale trials are underway; these also include 
measurements of biomarkers for AD and 
for assessing synaptic density. If indeed the 
improvement in memory is confirmed in 
future studies it may be possible to amplify 
this response by using novel, more potent 
P2Y receptor agonists, perhaps given along 
with the phosphatide precursors to enhance 
production of synaptic membrane.
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